The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery
Postoperative Nausea and Vomiting
About this trial
This is an interventional supportive care trial for Postoperative Nausea and Vomiting focused on measuring olanzapine, placebo-controlled, nausea, vomiting, ambulatory surgery procedures, antiemetic, general anesthesia
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Female aged 18-50 Scheduled to undergo ambulatory surgery under general anesthesia Access to smartphone device or computer with internet connection and has an email address Exclusion Criteria: Non-English speaking Unable to swallow pills Current use of anti-psychotic medications History of allergy to olanzapine Pregnancy/Lactation Current use of antihypertensive medication Diabetes Mellitus Clinically significant cardiovascular disease defined as follows: Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery. History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication. New York Heart Association Class II or higher congestive heart failure. Postural hypotension or vasovagal syncope within 6 months of planned surgery. Hypotension on day of surgery, defined as a systolic blood pressure < 90mmHg Seizure disorder Clinically active prolactinoma Hepatic disease Narrow angle glaucoma Parkinson's disease Lewy body dementia
Sites / Locations
- Yale New Haven HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Olanzapine
Placebo
olanzapine oral tablet, 5mg, once prior to surgery
placebo oral tablet once prior to surgery